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Abstract 
Fucosylation is an important type of glycosylation involved in cancer, and fucosylated proteins could be 
employed as cancer biomarkers. Previously, we reported that fucosylated N-glycans on haptoglobin in the 
sera of patients with pancreatic cancer were increased by lectin-ELISA and mass spectrometry analyses. 
However, an increase in fucosylated haptoglobin has been reported observed in various types of cancer. 
To ascertain if characteristic fucosylation is observed in each cancer type, we undertook site-specific 
analyses of N-glycans on haptoglobin in the sera of patients with five types of operable 
gastroenterological cancer (esophageal, gastric, colon, gallbladder, pancreatic), a non-gastroenterological 
cancer (prostate cancer) and normal controls using ODS column LC-ESI MS. Haptoglobin has four 
potential glycosylation sites (Asn184, Asn207, Asn211, Asn241). In all cancer samples, monofucosylated 
N-glycans were significantly increased at all glycosylation sites. Moreover, difucosylated N-glycans were 
detected at Asn 184, Asn207 and Asn241 in only cancer samples. Remarkable differences in N-glycan 
structure among cancer types were not observed. We next analyzed N-glycan alditols released from 
haptoglobin using graphitized carbon column LC-ESI MS to identify the linkage of fucosylation. 
Lewis-type and core-type fucosylated N-glycans were increased in gastroenterological cancer samples, 
but only core-type fucosylated N-glycan was relatively increased in prostate cancer samples. In metastatic 
prostate cancer, Lewis-type fucosylated N-glycan was also increased. These data suggest that the original 
tissue/cell producing fucosylated haptoglobin is different in each cancer type and linkage of fucosylation 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
3 
 
might be a clue of primary lesion, thereby enabling a differential diagnosis between gastroenterological 
cancers and non-gastroenterological cancers. 
 
This article contains supplementary materials as separate PDF file. 
 
Key words: fucosylated haptoglobin; gastroenterological cancer; metastatic prostate cancer; linkage of 
fucose; site-specific analysis 
 
Abbreviation: LC-ESI MS, liquid chromatography-electrospray ionization-mass spectrometry; Hpt, 
Haptoglobin; NV, normal volunteers; Eso, esophageal cancer; Gas, gastric cancer; Col, colon cancer; Pan, 
pancreatic cancer; Gal, gallbladder cancer; Pro, prostate cancer. 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
4 
 
Introduction 
Glycosylation is a critical post-translational modification of proteins. Fucosylation is an 
important event in glycosylation because it results in the formation of blood-type antigens and 
cancer-associated carbohydrate antigens [1]. Several researchers have reported that changes in glycan 
structures occur in pathologic conditions [2] and that the fucosylation of glycoproteins is associated with 
cancer and inflammation [3]. Hence, fucosylated target proteins have been identified [4] and considered 
to be potential tumor markers.  
Previously, we reported that fucosylated N-glycans on haptoglobin in the sera of patients with 
pancreatic cancer were increased according to analyses by lectin-enzyme-linked immunosorbent assay 
(lectin-ELISA) and mass spectrometry [5, 6]. Haptoglobin is an acute-phase protein produced in the liver 
and contains four glycosylation sites [7, 8]. In healthy individuals, most haptoglobin is not fucosylated [9, 
10] because a normal liver expresses low levels of fucosyltransferases and guanosine diphosphate fucose 
(GDP-Fuc, a common donor substrate for fucosyltransferases) [11]. Therefore, our report suggested that 
fucosylated N-glycan on haptoglobin could be a novel tumor marker. Until now, N-glycan on haptoglobin 
has been analyzed by various methods in patients with various types of cancer: hepatocellular carcinoma 
[12-15], lung cancer [16-19], pancreatic cancer [20-23], colon cancer [24, 25], gastric cancer [26], 
ovarian cancer [27-29], prostate cancer [30-32] and breast cancer [33, 34]. However, though samples 
derived from the same type of cancer were analyzed, each result was different because of disparities in 
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analytical strategy, including sample preparation and analytical method employed (e.g., lectin blotting, 
western blotting, liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS), 
high-performance liquid chromatography (HPLC) and capillary electrophoresis). To gain more accurate 
and comparable information of the N-glycan structures on haptoglobin (especially the fucosylation site 
and linkage) various types of cancer samples should be analyzed using the same analytical strategy. 
    To ascertain if characteristic fucosylation on haptoglobin is observed among different types of cancer, 
we undertook site-specific analyses of N-glycans on haptoglobin in the sera of patients with five types of 
operable gastroenterological cancers (esophageal, gastric, colon, gallbladder, pancreatic), a 
non-gastroenterological cancer (prostate) and normal controls. Furthermore, alditol N-glycans released 
from haptoglobin were analyzed using LC-ESI MS to identify and compare the linkage of fucosylation in 
each cancer sample. Identification of a characteristic fucosylation site and linkage in haptoglobin could be 
a novel type of cancer biomarker for the differential diagnosis of various types of cancer. 
 
Materials and Methods 
The study protocol was approved by the ethics committees of participating hospitals, Osaka 
University (Osaka, Japan) and Hiroshima University (Hiroshima, Japan). All patients provided have 
written informed consent to be included in this study.  
Lysylendopeptidase was purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan). 
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Sequencing-grade modified trypsin was obtained from Promega (Madison, WI, USA). Polyclonal rabbit 
anti-human haptoglobin antibody was purchased from DakoCytomation (Glostrup, Denmark). 
Endoprotease Glu-C (V8 protease) and Peptide-N4-(acetyl--D-glucosaminyl) asparagine amidase 
(PNGase F; E.C. 3.5.1.52, recombinant) were obtained from Roche Molecular Biochemicals (Tokyo, 
Japan). Alpha 1-3/4 fucosidase was purchased from Takara Bio Inc. (Shiga, Japan). Beta 1-4 galactosidase 
derived from Bacteroides fragilis and beta 1-3 galactosidase derived from Xanthomonas manihotis was 
obtained from New England Biolabs Japan Inc. (Tokyo, Japan). Other reagents were of the highest quality 
or LC/MS grade available commercially. 
 
Serum samples 
Serum samples from normal volunteers (NV; n=5; aged 40–70 years) and from patients with 
esophageal cancer (Eso; n=5; 40–70 years; stage II or III; no metastasis and the tumor was operable), 
gastric cancer (Gas; n=6; 40–70 years; stage II or III; no metastasis and the tumor was operable), colon 
cancer (Col; n=18; 43–77 years; detailed information of patients shown in Supplementary Table 1), 
pancreatic cancer (Pan; n=5; 40–70 years; stage II–IV; no metastasis and tumor was operable), 
gallbladder cancer (Gal; n=6; 40–70 years; stage II or III; no metastasis and tumor was operable) and 
prostate cancer (Pro; n=26; patients named “Pro 1–7” were 40–70 years, stage II or III, no metastasis and 
operable; patients named “Pro 8–26” were 53–83 years, stage I–III; detailed information for Pro 8–26 
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shown in Supplementary Table 2) were obtained from Osaka University-related Hospitals. Serum samples 
were stored at −80°C until use.  
 
Cell culture  
An expression vector of human haptoglobin (pCDNA) was transfected into the human colon 
cancer cell line WiDr. Cells were grown in Dulbecco’s modified Eagle’s medium (Wako Pure Chemical 
Industries Ltd.) supplemented with 10% fetal bovine serum (FBS) and 300 g/ mL hygromycin 
(Sigma-Aldrich, St Louis, MO, USA) at 37°C in an atmosphere of 5% CO2. Single clones of WiDr cells 
expressing high levels of haptoglobin were used for subsequent experiments. When cell lines had reached 
80% confluence, each medium was replaced by antibiotic- and FBS-free medium after washing twice to 
remove FBS. Then, cell lines were incubated at 37°C in an atmosphere of 5% CO2 for 3 days, followed 
by collection of the conditioned media (which contained haptoglobin). 
 
Purification of haptoglobin from human sera and cell cultured media 
    The procedure for purification of haptoglobin from sera was conducted as described in detail 
previously [6]. Briefly, the sera of patients with various types of cancer (100 L) and NV (300 L) were 
passed through a 0.45-µm cellulose acetate filter and diluted with buffer A (50 mM sodium phosphate 
buffer (pH 7.4), 0.5 M NaCl, 0.02% NaN3) to a final volume of 7 mL. Diluted serum samples were passed 
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five times through a human haptoglobin affinity column coupled with 300 L of anti-human haptoglobin 
antibody at room temperature using a peristaltic pump. In the case of the culture medium, 250 mL of the 
medium containing haptoglobin was centrifuged at 220 g for 5 min and the supernatant filtered. The 
filtrated medium was circulated on the anti-human haptoglobin affinity column overnight at 4°C. After 
washing the column with 15 mL of buffer A, followed by 5 mL of elution buffer (100 mM glycine, 0.5 M 
NaCl, pH 3.0), the haptoglobin bound to the column was eluted. The eluate was neutralized immediately 
with 100 L of 2 M Tris-HCl (pH 8.0). The neutralized eluate containing haptoglobin was desalted using 
a PD-10 column (GE Healthcare, Piscataway, NJ, USA) equilibrated with water. One-twentieth of the 
desalted water containing haptoglobin derived from sera or the cell cultured medium was subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 10% polyacrylamide) under 
reduced conditions and then stained with Coomassie Brilliant Blue to confirm purification of haptoglobin. 
The remaining haptoglobin in the water was evaporated to dryness for subsequent analyses of 
glycopeptides and alditol N-glycans.  
 
Preparation of desialo-glycopeptide of haptoglobin 
    The purified haptoglobin residue was dissolved in 500 µL of a reducing solution containing 250 mM 
Tris-HCl (pH 8.5), 6 M guanidine hydrochloride, 2 mM ethylenediamine tetra-acetic acid (EDTA) and 10 
mg of dithiothreitol. The mixture was incubated at 50°C for 1 h to reduce cysteine residues. After the 
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addition of 20 mg of iodoacetamide to the mixture, the reaction was allowed to continue for 30 min at 
room temperature in the dark. The reaction mixture was pass through a Nap-5 column (GE Healthcare) 
equilibrated with water to remove salts from the reducing solution and excess iodoacetamide. The eluate 
containing S-carbamidomethylated haptoglobin (1 mL in water) was evaporated to dryness. The residue 
was dissolved with 100 L of 50 mM NH4HCO3 containing an enzyme mixture of lysylendopeptidase (2 
g) and trypsin (2 g) and incubated for 16 h at 37°C. After boiling, the solution was mixed with 
endoprotease Glu-C (2 µg in 2 µL of 50 mM NH4HCO3). The mixture was incubated for 16 h at 37°C and 
then boiled. To enrich glycopeptides, affinity separation by partitioning with Sepharose CL4B [35] was 
conducted. Briefly, water (100 L) was added to the boiled solution, and the solution mixed with 1 mL of 
an organic solvent (1-butanol/ethanol; 4:1; v/v). The mixture was added to a 1.5-mL polypropylene tube 
containing a 100-L packed volume of Sepharose CL4B equilibrated with 1-butanol/ethanol/water (4:1:1, 
v/v). After gentle agitation for 30 min, the gel was washed thrice with 1 mL of the same organic solvent. 
Then, the Sepharose CL4B gel was mixed gently with 400 L of aqueous solvent, ethanol/water (1:1, v/v), 
and the liquid phase collected in the polypropylene tube. Four-hundred microliters of the same aqueous 
solvent was added to the gel again, and then shaken gently for 5 min. Then, the liquid phase was 
combined and evaporated to dryness. For desialylation, the residue was dissolved in 2 M acetic acid (200 
L) and incubated for 2 h at 80°C. The solution was evaporated to dryness for LC-ESI MS analyses. 
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LC-ESI MS analyses of the desialo-glycopeptides of haptoglobin 
    Dried desialo-glycopeptides were dissolved in 20 L of 0.08% formic acid. Desialo-glycopeptides 
were separated using an ODS column (Develosil 300ODS-HG-5; 150 × 1.0 mm ID; Nomura Chemicals, 
Aichi, Japan) under specific gradient conditions. The mobile phases were solvent A (0.08% formic acid) 
and solvent B (0.15% formic acid in 80% acetonitrile). The column was eluted with solvent A for 5 min, 
at which point the concentration of solvent B was increased to 40% over 55 min at a flow rate of 50 
L/min using an Accela HPLC system (Thermo Fisher Scientific, Boston, MA, USA). The eluate was 
introduced continuously into an ESI source, and the glycopeptides were analyzed by LTQ Orbitrap XL 
(hybrid linear ion trap-orbitrap mass spectrometer; Thermo Fisher Scientific). In the MS setting, the 
voltage of the capillary source was set at 4.5 kV, and the temperature of the transfer capillary maintained 
at 300°C. The capillary voltage and tube lens voltage were set at 15 V and 50 V, respectively. MS data 
were obtained in positive ion mode over the mass range m/z 300 to m/z 3000 (resolution: 60000, mass 
accuracy: 5 ppm). MS/MS data were obtained by ion trap in LTQ Orbitrap XL (data dependent top 3, 
CID).  
 
Relative quantitation of the glycoforms on each glycosylation site of haptoglobin 
Quadruply charged ions [M+4H]4+ for site 1 or 4 and triply charged ions [M+3H]3+ for site 2 or 
3 were selected for the relative quantitation of the glycoforms on each site. The peak intensity of highest 
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isotope (not limited to monoisotope) of the corresponding glycoform in overall mass spectra was 
calculated using Xcalibur software ver. 2.0.7. (Thermo Fisher Scientific) by matching observed 
monoisotopic mass to theoretical monoisotopic mass (GlycoMod tool, http://web.expasy.org/glycomod/, 
mass tolerance; +/- 0.01 Da) and also by confirming with MS/MS data (only for data dependent top 3 
peaks). Although other charge state ions of the corresponding glycoforms were observed on each site, we 
chose quadruply charged ions for site 1 or 4 and triply charged ions for site 2 or 3, because their charge 
states provided the highest intensities of glycopeptide peaks on each site. Improving signal-to-noise ratio 
by using highest intensity charge state must lead to an increase in number of detectable minor 
components such as di-fucosylated glycopeptides. 
 
Preparation of alditol -glycans of haptoglobin for analyses of fucosylation linkage 
    Purified haptoglobin from pooled sera was dissolved in 100 L of water. This solution was dotted 
(2.5 μL × 4 times) onto a polyvinylidene difluoride (PVDF) membrane activated with ethanol. For 
haptoglobin derived from the WiDr medium, purified haptoglobin was dissolved in 10 L of water, and 
then subjected to SDS-PAGE (10% polyacrylamide) under reduced conditions. Proteins on one gel were 
transferred to a PVDF membrane under semi-dry conditions by means of a HorizeBLOT 2M-R system 
(Atto Corp., Tokyo, Japan). The PVDF membrane was dried at room temperature overnight, washed with 
ethanol for 1 min, and then washed thrice for 1 min with water. To stain proteins, the membrane was 
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incubated for 5 min with Direct Blue 71 (800 μL solution A: 0.1% (w/v) Direct Blue 71 (Sigma–Aldrich) 
in 10 mL solution B :acetic acid:ethanol:water at 1:4:5). After destaining with solution B for 1 min, the 
PVDF membrane was dried at room temperature for >4 h. N-glycans were released from the dot-blotted 
or transferred proteins by the method of Wilson et al. [36] with some modifications by Nakano et al. [37]. 
The spots/bands of haptoglobin stained blue were cut out and placed in the separate wells of a 96-well 
microtiter plate. Then, the spots/bands were blocked with 100 L of 1% (w/v) polyvinylpyrrolidone 
40,000 in 50% (v/v) methanol, agitated for 20 min, and washed with water (100 L × 5 times). PNGase F 
(2U in 10 L of 100 mM phosphate buffer (pH 7.3), 25 mM of EDTA) was added to each well and 
preincubated at 37°C for 15 min. Then, 10 L of water was added to each well and incubated at 37°C 
overnight to release N-glycans. During incubation, the 96-well plate was sealed with amplification tape to 
prevent evaporation. To collect released N-glycans, the plate were sonicated for 10 min and the solution 
containing released N-glycans (20 L) transferred to 1.5-mL polypropylene tubes. The sample well was 
washed with water (50 μL × 2) and the washings combined. To transform the reducing end 1-amino 
N-acetylglucosamine to an N-acetylglucosamine after PNGase F release, ammonium acetate buffer (100 
mM, pH 5.0, 20 L) was added to the released N-glycans solution for 1 h at room temperature. After 
evaporation to dryness, the glycans were dissolved with 20 L of 1 M NaBH4 in 50 mM KOH and 
reduced at 50°C for 3 h to convert into N-glycan alditols. One microliter of acetic acid was added to stop 
the reaction, and N-glycan alditol solution was desalted using a cation-exchange column (35 L). The 
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column was washed twice with 50 L of water to pass through the N-glycan alditols completely. After 
drying the desalted N-glycan alditol solution, borate contained in the sample was removed by the addition 
of 100 L methanol and dried under a vacuum thrice. To remove sialic acid, the residue was dissolved in 
2 M acetic acid (200 µL) and incubated for 2 h at 80°C. The solution was evaporated to dryness. 
 
LC-ESI MS analyses of the N-glycan alditols of haptoglobin 
    Dried N-glycan alditols were resuspended in 10 mM NH4HCO3 (15 L) immediately before LC-ESI 
MS analyses. N-glycan alditols were separated using a porous graphitized carbon column (5 m 
HyperCarb, 100 × 1.0 mm ID, Thermo Fisher Scientific) under specific gradient conditions. Separation of 
N-glycans was achieved using a sequence of isocratic and two segmented linear gradients: 0–8 min, 10 
mM NH4HCO3; 8–38 min, 6.75–15.75% (v/v) CH3CN in 10 mM NH4HCO3; 38–73 min, 15.75–40.5% 
(v/v) CH3CN in 10 mM NH4HCO3; and increasing to 81% (v/v) CH3CN in 10 mM NH4HCO3 for 10 min 
and re-equilibration with 10 mM NH4HCO3 for 6 min. The HPLC flow rate through the column was 50 
μL/min using an Accela HPLC system (Thermo Fisher Scientific). With regard to mass spectrometer 
(LTQ Orbitrap XL), the voltage of the capillary source was set at 4.5 kV, and the temperature of the 
transfer capillary was maintained at 300°C. The capillary voltage and tube lens voltage were set at 18 V 
and 110 V, respectively. MS spectra were obtained in the positive ion mode using Orbitrap (mass range 
m/z 500 to m/z 2500), and MS/MS spectra were obtained using Iontrap after collision-induced 
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dissociation. Monoisotopic masses were assigned with possible monosaccharide compositions using the 
GlycoMod tool available on the ExPASy server (http://au.expasy.org/tools/glycomod; mass tolerance for 
precursor ions is ± 0.02 Da) and the proposed glycan structures were further verified through annotation 
using a fragmentation mass matching approach based on the MS/MS data by Xcalibur software ver. 2.0.7. 
(Thermo Fisher Scientific). 
 
Results 
Glycosylation site-specific analyses of haptoglobin by LC-ESI MS  
    To investigate if characteristic N-glycan structures were present among samples of various types of 
cancer, site-specific analyses of haptoglobin N-glycans were carried out using serum samples from 
patients with five types of gastroenterological cancer (Eso, Gas, Col, Gal, Pan), a non-gastroenterological 
cancer (Pro) and NV. Haptoglobin purified from sera was digested with a combination of trypsin, 
lysylendopeptidase and endopeptidase Glu-C after reduction and alkylation. Glycopeptides were enriched 
and desialylated, and the desialylated glycopeptides analyzed by LC-ESI MS. In theory, the glycopeptides 
digested with these three proteases should be: Met179-Glu194 including one glycosylation site (site 1: 
Asn184); Asn203-Glu210 including one glycosylation site (site 2: Asn207); Asn211-Lys215 including 
one glycosylation site (site 3: Asn211); and Val236-Asp246 including one glycosylation site (site 4: 
Asn241). The representative mass chromatogram for these four glycopeptide clusters for each 
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glycosylation site is shown in Fig. 1. Glycopeptides from these four clusters include various desialylated 
N-glyans shown in Fig. 2. The average mass spectra during 2.5–3.5 min for glycopeptide cluster of site 3 
are shown in Fig. 3a. The abbreviations for N-glycan structures in the glycopeptides are summarized in 
Fig. 2. For example, the peptide containing the tri-antennary N-glycan with one Fuc residue is represented 
as “3-F”. The first numeral indicates the branch number (tri-antennary in this case) and “F” indicates one 
Fuc residue. “0” denotes the absence of Fuc. Six glycopeptides (2-0, 2-F, 3-0, 3-F, 4-0, 4-F) were detected 
as mainly triply charged ion–proton adducts at site 3 in samples of various types of cancer and NV 
samples. The peak intensity of highest isotope (not limited to monoisotope) of the corresponding 
glycoform for site 3 in overall mass spectra was identified and calculated according to procedure 
described in material and methods section and Fig. 2. The peak intensities were shown in 
Fig. 3b. Total peak intensity of glycoform was set to 100% on each sample, and then the 
relative percentage of each glycoform was calculated and shown in Fig. 3c. In Figure 3, at site 3, 
fucosylated N-glycans (3-F, 4-F) were increased in samples of all types of cancer compared with NV 
samples. At site 1 and site 4, glycopeptides were detected as mainly quadruply charged ion–proton 
adducts (data not shown). At site 2, glycopeptides were detected as mainly triply charged ion–proton 
adducts (data not shown). For the comparison with NV, the ratio of fucosylated N-glycans was calculated 
based on the non-fucosylated corresponding N-glycan peaks at each site for all samples. For example, in 
case of tetra-antennary N-glycan at site 3 for NV #1 sample shown in Fig. 3,  the ratio of 
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monofucosylated N-glycan (4-F) to the non-fucosylated N-glycan (4-0) is 320/4880 (= 0.0656). The 
results obtained from all samples are summarized in Fig. 4 and Supplementary Figs 1-4. Fucosylated 
N-glycans tended to increase at all glycosylation sites in cancer samples. At site 1, highly branched 
N-glycans (especially tetra-antennary N-glycans) were barely observed compared with those at other sites. 
In contrast, highly branched N-glycans (3-0 and 4-0) were the main ones at site 3, so fucosylated 
N-glycans (3-F, 3-FF, 4-F and 4-FF) could increase at site 3. In Eso samples, 3-FF and 4-F at site 2 as 
well as 2-F and 3-F at site 4 were significantly increased compared to NV samples (p<0.01). In Gas 
samples, 3-FF and 4-F at site 2 as well as 3-F and 4-F at site 3 were significantly increased compared with 
NV samples (p<0.01). In Col samples, 3-FF and 4-FF at site 2, 3-F and 4-F at site 3 and 2-F and 4-F at 
site 4 were significantly increased compared with NV samples (p<0.01). In Pan samples, 4-F at site 2 was 
significantly increased compared with NV samples (p<0.01). In Gal samples, 4-F at site 3 was 
significantly increased compared with NV samples (p < 0.01). In Pro samples, 3-FF at site 2, 4-F at site 3 
as well as 3-FF and 4-F at site 4 were significantly increased compared with NV samples (p<0.01). 
Non-fucosylated bi-antennary N-glycan (2-0) was significantly increased at site 1 only in Gas samples. 
Tri- and tetra-antennary N-glycan with two Fuc (3-FF and 4-FF) were observed at sites 1, 2 and 4 only in 
cancer samples. These difucosylated N-glycans (3-FF and 4-FF) at site 3 could not be detected. The 
reason for non-detection of difucosylated N-glycans at site 3 was overlapping of small amounts of 
miss-cleavaged monosialylated site 3 glycopeptides. This was because glycopeptides including site 3 
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were eluted very early and not separated on the ODS column according to differences in glycan structures. 
At other sites, miss-cleavaged sialylated glycopeptides were not observed.  
These results showed that the frequency of fucosylation at each site was different among the 
different types of cancer, but a site and glycan structure that increased fucosylation specifically in a 
particular type of cancer was not observed. 
 
Identification of the linkage of fucosylation 
Fucosylated N-glycans were increased in cancer samples compared with NV samples. To 
ascertain if the linkage type of fucosylation in increased fucosylated N-glycans among cancer types was 
different, N-glycans were released from purified haptoglobin by PNGase F and were analyzed by LC-ESI 
MS as N-glycan alditols. The BPC of N-glycan alditols (Fig. 5a) showed different glycoforms with 
different peaks among NV samples and cancer samples. Robust peaks at 35, 40 and 41 min were due to 
2-0, 3-0 and 4-0, respectively. Many types of fucosylated N-glycan alditols (which are Lewis fucosylated 
bi-, tri- and tetra-antennary glycans and core fucosylated bi-, tri and tetra-antennary glycans) were 
detected as weak peaks in the BPC (Fig. 5a). This BPC showed that the ratio of fucosylated N-glycans on 
haptoglobin was increased in each cancer type sample. The EIC at m/z 1077.90–1077.92 (Fig. 5b) 
represented [M+2H]2+ of the monofucosylated tri-antennary N-glycan alditol. It showed differences in the 
relative abundance of Lewis fucosylated tri-antennary N-glycan alditol (3-F(L), 37 min) and core 
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fucosylated tri-antennary N-glycan alditol (3-F(C), 44 min) between NV and cancer samples. Linkage of 
fucosylation was confirmed by digestion of fucosylated N-glycan alditol with 1-3/4 fucosidase 
(Supplementary Fig. 5). The EIC in Fig. 5b showed that Lewis fucosylated N-glycans were more 
abundant than core fucosylated N-glycans in five types of gastroenterological cancers (Eso, Gas, Col, Pan, 
Gal). In contrast, in a non-gastroenterological cancer (Pro), core-fucosylated N-glycans were more 
abundant than Lewis fucosylated N-glycans, which was the same pattern as with NV samples (although 
total amount of fucosylated N-glycans was different between NV samples and Pro samples). The increase 
in Lewis fucosylated N-glycans in gastroenterological cancer samples was also observed in bi- and 
tetra-antennary N-glycans (Supplementary Fig. 6). In samples of the non-gastroenterological cancer (Pro), 
a relative increase in Lewis fucosylated N-glycans was not observed instead, a relative increase in core 
fucosylated N-glycans was noted. In conclusion, analyses of N-glycan alditols demonstrated that linkage 
of fucosylation of haptoglobin derived from sera of patients with prostate cancer was different from those 
of gastroenterological cancer. 
 
Change in linkage type of fucosylation by cancer metastasis 
    Among non-metastatic cancer samples, only the Pro sample showed different fucosylation patterns, 
i.e., core fucosylated N-glycans were more abundant than Lewis fucosylated N-glycans (Fig. 5b). To 
investigate the influence of metastasis on linkage of fucosylation, we analyzed N-glycan alditols released 
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from metastatic Pro samples. The EIC of fucosylated tri-antennary N-glycan alditol (m/z 1077.90–
1077.92) is shown in the bottommost panel of Fig. 5. This EIC in Fig. 5b demonstrated that, in metastatic 
Pro samples, Lewis-fucosylated N-glycan rather than core-fucosylated N-glycan was in the majority. This 
trend was also observed in fucosylated tetra-antennary N-glycans (bottommost panel in Supplementary 
Fig. 6). These results suggested that cancer metastasis transformed the linkage type of fucose from 
core-fucosylation to Lewis-fucosylation in Pro samples. 
 
Comparison of the glycan structure of haptoglobin derived from a colon cancer cell line and from the 
sera of patients with colon cancer 
In our previous study, the mechanism underlying production of fucosylated haptoglobin in Pan 
was studied [5]. Expression of haptoglobin mRNA was observed in a small number of Pan cell lines, 
suggesting that each cancer cell produced fucosylated haptoglobin. To investigate this possibility, we 
stably transfected the haptoglobin gene to a human colon cancer cell line (WiDr) to construct WiDr 
cell-expressing haptoglobin. After WiDr cells were cultured, haptoglobin was purified from the 
conditioned medium. Purified haptoglobin from WiDr cultured media (Cell-Hpt) and sera of patients with 
Col (Serum-Hpt) were separated from contaminant proteins by SDS-PAGE and transferred to PVDF 
membranes. N-glycans were released from haptoglobin on PVDF membranes by PNGase F and analyzed 
by LC-ESI MS as N-glycan alditols. In the BPC in Fig. 6a, Cell-Hpt samples and Serum-Hpt samples 
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showed identical elution patterns with the same peaks of N-glycan structures. Comparison of the ratio of 
core- and Lewis-fucosylated N-glycans of Cell-Hpt with that of Serum-Hpt, the EIC of fucosylated 
tri-antennary N-glycans (m/z 1077.90-1077.92) is presented in Fig. 6b. This EIC showed that the ratio of 
core- and Lewis-fucosylated N-glycans were approximately identical. In fucosylated bi-antennary and 
tetra-antennary N-glycans, the ratio of core- and Lewis-fucosylated N-glycan was similar between 
Cell-Hpt and Serum-Hpt (Supplementary Fig. 7). 
    These results demonstrated that the ratio of core-fucosylation and Lewis-fucosylation was not 
noticeably different between haptoglobin derived from a Col cell line and from the sera of patients with 
Col, suggesting that serum fucosylated haptoglobin in patients with colon cancer could be produced from 
colon cancer cells. 
 
Discussion 
    Since we reported that fucosylated haptoglobin might be a novel tumor marker [5, 6], several 
researchers have studied fucosylated N-glycans on haptoglobin. However, information regarding 
comparable fucosylated N-glycan structures among various types of cancer has not been obtained because 
each research team used different methods to analyze N-glycans on haptoglobin. Here, we analyzed 
N-glycans on haptoglobin in the sera of patients with five types of gastroenterological cancers (Eso, Gas, 
Col, Gal and Pan), a non-gastroenterological cancer (Pro) and normal controls using the same analytical 
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method to ascertain if characteristic fucosylation is observed in each type of cancer. Site-specific analyses 
revealed fucosylated N-glycans to be increased in cancer samples compared with NV samples, but 
characterizing the type of cancer by fucosylation linkage or fucosylation site of N-glycans on haptoglobin 
was difficult. Next, we analyzed the N-glycan alditols released from haptoglobin to identify the linkage of 
fucosylation. Lewis-fucosylated N-glycans were abundant in gastroenterological cancers (Eso, Gas, Col, 
Gal and Pan), whereas core-fucosylated N-glycans were abundant in prostate cancer. 
    Our previous study [5] suggested two mechanisms underlying the production of fucosylated 
haptoglobin: (i) each cancer cell and (ii) the liver (which then secreted it into blood). If almost all 
fucosylated haptoglobin in the sera of patients is derived from cancer cells, distinct differences in 
N-glycan structure should be observed because the glycosyltransferase expression involved in branch 
formation (and fucosylation) is different in each organ/tissue. However, remarkable differences in the 
structure or fucosylation of N-glycan were not detected in five types of gastroenterological cancers. This 
result suggested that almost all of the fucosylated haptoglobin in the sera of cancer patients might be 
produced in the liver. The fucosylated haptoglobin derived from cancer cells might be too minor 
component to change the trends of glycosylation (including fucosylation). 
    In a healthy liver, core-fucosylated proteins produced from normal hepatocytes go to the apical side 
and are secreted into the bile duct [38]. In a micro-metastasized liver, core-fucosylated proteins secreted 
into blood cause destruction of the cellular polarity of hepatocytes [38]. It is well known that 
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gastroenterological cancers tend to metastasize to the liver. We used non-metastatic gastroenterological 
cancer samples in the present study. Therefore, core-fucosylated N-glycans in sera were probably not 
increased. Instead, Lewis-fucosylated N-glycans were increased in the sera of patients with 
non-metastatic gastroenterological cancers. The reason for this increase in Lewis-fucosylated N-glycans 
was probably an increase in 1-3 fucosyltransferases such as FUT4 and FUT6 in the liver. An alternate 
reason could be an increase in secretion of Lewis-fucosylated N-glycans into blood from 
gastroenterological cancer cells due to FUT3-, FUT4- and FUT6-catalyzed 1-3/4 fucosylation [39, 40]. 
In our next study, we wish to confirm that core-fucosylated N-glycans on haptoglobin are increased in the 
sera of patients with metastatic gastroenterological cancers. 
     In contrast to gastroenterological cancers, it is well known that Pro cancer tends to metastasize to 
the bone and not to the liver. Therefore, the cellular polarity of hepatocytes is not destroyed in subjects 
with metastatic Pro cancer. In the present study, increases in core-fucosylated N-glycans in the sera of 
patients with metastatic Pro cancer was not observed instead, a decrease of core-fucosylated N-glycans 
was noted. This result suggests that core-fucosylated haptoglobin in the sera of patients with Pro cancer 
was produced mainly in the liver. However, we observed that the mRNA of haptoglobin and FUT8 
(catalyzed 1-6 fucosyltransferase) was expressed in a Pro cancer cell line [41]. Therefore, a portion of 
haptoglobin containing core-fucosylated N-glycans may be produced in Pro cancer cells. When Pro 
cancer cells metastasized, the ratio of Lewis-fucosylation and core-fucosylation of haptoglobin in the sera 
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of patients was inverted. In general, Lewis-fucosylation is very important for cancer cells to metastasize 
to another tissue because sialyl Lewis fucose is a ligand for selectin (a key molecule for metastasis). 
Some research teams have reported that expression of 1-3 fucosyltransferases such as FUT6 and FUT7 
in Pro cancer cells support metastasis to bone [42, 43]. Therefore, haptoglobin produced from metastatic 
Pro cancer cells might be highly Lewis-fucosylated. 
 The present study showed that the simultaneous and comparative analyses of N-glycans on 
haptoglobin in the sera of patients with various types of cancer were useful to find differential marker of 
cancers. Significant difference in the structure of haptoglobin N-glycan was not detected among 
gastroenterological cancers, which enabled the differential diagnosis among gastroenterological cancers, 
in this study. However, the remarkable difference in the linkage of fucosylation in haptoglobin N-glycan 
was detected between gastroenterological cancers and non-gastroenterological cancer (Pro). Moreover, 
we found the linkage of fucosylation in haptoglobin N-glycan was different between localized and 
metastatic Prostate cancer samples.  
Although detail mechanisms for fucosylation changes of haptoglobin remain unknown, it is 
important to know which cells produce fucosylated haptoglobin in patients with prostate cancer 
with/without metastasis. Further study is required to identify fucosylated haptoglobin 
immunohistochemically. 
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Figure legends  
 
Fig. 1 Base peak chromatogram (BPC) of haptoglobin sample (this is representative data for Col 
#12) Four desialo-glycopeptide peaks were observed at 2.99 (site 3: Asn211), 36.41 (site 4: Asn241), 
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37.18 (site 2: Asn207) and 38.08 min (site 1: Asn184).  
 
Fig. 2 Abbreviations, structures, theoretical mass and observed mass for desialo-glycopeptides and  
N-glycan alditols detected in this study Desialo-glycopeptides which include sites 1 or 4 are calculated 
as quadruply charged ions, and those which include site 2 or 3 are calculated as triply charged ions. 
N-glycan alditols are calculated as doubly charged ions. *Presence of these glycopeptides was 
indeterminable cause of overlapping of small amounts of miss-cleavaged monosialylated their 
glycopeptides. 
 
Fig. 3 Relative amount of N-glycans in glycopeptide cluster for site 3 derived from normal volunteer 
sample and various cancer samples. (a) Average mass spectra during 2.5-3.5 min for site 3. (b) Highest 
isotope peak intensity of the corresponding N-glycan in overall mass spectra for site 3. (c) Relative 
percentage of N-glycan at sites 3 after setting total peak intensity shown in (b) to 100% on each sample. 
In fig. (a), table (b) and graph (c), NV (normal volunteer) #1, Eso (esophageal cancer) #2, Gas (gastric 
cancer) #4, Col (colon cancer) #9, Pan, (pancreatic cancer) #5, Gal (gallbladder cancer) #7, and Pro 
(prostate cancer) #25 were used for representative data. Abbreviations for glycan structures are 
summarized in Fig. 2. 
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Fig. 4 Ratio of glycopeptide fucosylated-glycoform to non-fucosylated-glycoform at each 
glycosylation site Glycopeptides were derived from haptoglobin purified from the sera of patients with 
Eso (n=5), Gas (n=6), Col (n=18), Pan (n=5), Gal (n=6), Pro ( n=26) and sera of NV (n=5). This ratio was 
calculated based on dividing peak intensity of highest isotope peak of fucosylated N-glycan by that of the 
corresponding non-fucosylated N-glycan. The glycoform abbreviations in this figure are summarized in 
Fig. 2. To compare NV and various cancer samples, the unpaired Student’s t-test (two-tailed) was used. 
The annotations with a single asterisk denote p<0.05, and double asterisks denote p<0.01. 
 
Fig. 5 LC-ESI MS analyses of N-glycan alditols released from haptoglobin of normal volunteer 
samples (NV), 5 types of non-metastatic gastroenterological cancer samples (Eso_pool, Gas_pool, 
Col_pool, Pan_pool, Gal_pool), non-metastatic non-gastroenterological cancer samples (Pro_#18) 
and metastatic non-gastroenterological (Pro-Meta_#14) (a) The BPC obtained from analyses of 
various cancer samples and normal volunteer samples. (b) The EIC at m/z 1077.90–1077.92 suggests 
monofucosylated tri-antennary N-glycan alditol obtained from analyses of various cancer samples and 
normal volunteer samples. Lewis-fucosylated di, tri and tetra-antennary N-glycan (2-F(L), 3-F(L) and 
4-F(L)) and core-fucosylated di, tri and tetra-antennary N-glycan (2-F(C), 3-F(C) and 4-F(C)) were 
assigned from the results of digestion with 1-3/4 fucosidase shown in Sup. Fig. 5. 
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Fig. 6 LC-ESI MS analyses of N-glycan alditols released from haptoglobin in the sera of patients 
with colon cancer (Serum-Hpt) and haptoglobin produced by a human colon carcinoma cell line 
(Cell-Hpt) (a) The BPC obtained from analyses of N-glycan alditols derived from purified haptoglobin 
from serum (Serum-Hpt) or cultured media (Cell-Hpt). (b) The EIC at m/z 1077.90–1077.92 indicate a 
monofucosylated tri-antennary N-glycan alditol obtained from analyses of Serum-Hpt and Cell-Hpt.  
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Pro sample 
No.
Age 
(years) PSA
Gleason score (GS) TNM classification
Total GS primary GS
secondary 
GS T N M
8 65 14 7 4 3 3b 0 0
9 68 7.4 7 4 3(5) 2c 0 0
10 75 4 9 5 4 3b 0 0
11 78 3.11 9 4 0 0
12 68 4.96 9 4 5 3b 0 0
13 68 1128 8 4 4 3a 1 1
14 79 10885 8 4 4 3b 1 1
15 77 390 8 4 4 3a 1 0
16 77 16.03 8 4 4 1c 0 0
17 72 13.9 7 3 4 2c 0 x
18 68 4.64 8 4 4 2a 0 0
19 67 6.74 7 3 4 1ｃ 0 0
20 71 8.93 9 4 5 3a 0 0
21 64 21 9 4 5 2c 0 0
22 72 23.3 7 3 4(5) 3a 0 0
23 83 128 9 4 5 3a 0 0
24 53 6.2 8 3 5 2c 0 0
25 79 108 6 3 3 1c 1 1
26 64 4.37 6 3 3 2c 0 0
Supplementary Table 2
Clinical information of prostate cancer samples 
Col sample no. Stage
1 IV
2 IIIa
3 IIIa
4 IV
5 IV
6 IIIb
7 IIIb
8 I
9 II
10 IIIa
11 IIIa
12 I
13 IV
14 II
15 I
16 II
17 II
18 II
Supplementary Table 1
Stage of colon cancer samples 
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Supplementary Fig. 1.  Ratio of glycopeptide fucosylated glycan to non-fucosylated glycan at 
site 1.  Glycopeptides were derived from haptoglobin purified from the sera of patients with 
esophageal cancer (Eso; n=5), gastric cancer (Gas; n=6), colon cancer (Col; n=18), 
pancreatic cancer (Pan; n=5), gallbladder cancer (Gal; n=6), prostate cancer (Pro; n=26) and 
sera of normal volunteers (NV; n=5). This ratio was calculated based on the signal intensities 
of the corresponding glycopeptides in site-specific analyses. Abbreviations in this figure are 
summarized in Fig. 2. To compare NV and various cancer samples, unpaired Student’s t-test 
(two-tailed) was used. Annotations with a single asterisk denote p<0.05, and double asterisks 
denote p<0.01.
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Supplementary Fig. 2.  Ratio of glycopeptide fucosylated glycan to non-fucosylated glycan at 
site 2.  Glycopeptides were derived from haptoglobin purified from the sera of patients with 
esophageal cancer (Eso; n=5), gastric cancer (Gas; n=6), colon cancer (Col; n=18), 
pancreatic cancer (Pan; n=5), gallbladder cancer (Gal; n=6), prostate cancer (Pro; n=26) and 
sera of normal volunteers (NV; n=5). This ratio was calculated based on the signal intensities 
of corresponding glycopeptides in site-specific analyses. Abbreviations in this figure are 
summarized in Fig. 2. To compare NV and various cancer samples, unpaired Student’s t-test 
(two-tailed) was used. Annotations with a single asterisk denote p<0.05, and double asterisks 
denote p<0.01.
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Supplementary Fig. 3.  Ratio of glycopeptide fucosylated glycan to non-fucosylated glycan at 
site 3.  Glycopeptides were derived from haptoglobin purified from the sera of patients with 
esophageal cancer (Eso; n=5), gastric cancer (Gas; n=6), colon cancer (Col; n=18), 
pancreatic cancer (Pan; n=5), gallbladder cancer (Gal; n=6), prostate cancer (Pro; n=26) and 
sera of normal volunteers (NV; n=5). This ratio was calculated based on the signal intensities 
of corresponding glycopeptides in site-specific analyses. Abbreviations in this figure are 
summarized in Fig. 2. To compare NV and various cancer samples, unpaired Student’s t-test 
(two-tailed) was used. Annotations with a single asterisk denote p<0.05, and double asterisks 
denote p<0.01. Presence of 3-FF and 4-FF was indeterminable cause of overlapping of tiny 
miss-cleavaged monosialylated their glycopeptides.
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Supplementary Fig. 4.  Ratio of glycopeptide fucosylated glycan to non-fucosylated glycan at 
site 4.  Glycopeptides were derived from haptoglobin purified from the sera of patients with 
esophageal cancer (Eso; n=5), gastric cancer (Gas; n=6), colon cancer (Col; n=18), 
pancreatic cancer (Pan; n=5), gallbladder cancer (Gal; n=6), prostate cancer (Pro; n=26) and 
sera of normal volunteers (NV; n=5). This ratio was calculated based on the signal intensities 
of corresponding glycopeptides in site-specific analyses. Abbreviations in this figure are 
summarized in Fig. 2. To compare NV and various cancer samples, unpaired Student’s t-test 
(two-tailed) was used. Annotations with a single asterisk denote p<0.05, and double asterisks 
denote p<0.01.
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Supplementary Fig. 5. The EIC of 
glycan alditol released from human 
haptoglobin. Upper panel shows the 
result of a control sample (non-digested 
sample) and lower panel the result of a 
digested sample with 1-3/4 fucosidase.  
The EIC at m/z 895.33–895.35, at m/z
1077.90–1077.92 and at m/z 1260.46–
1260.48 indicates mono fucosylated bi-, 
tri- and tetra-antennary N-glycan 
alditols, respectively. In each EIC, the 
former peaks disappeared upon 
digestion with 1-3/4 fucosidase. These 
results demonstrated that the former 
peaks were Lewis-fucosylated N-glycan 
and the latter peaks were core-
fucosylated N-glycan.
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Supplementary Fig. 6. The EIC of N-glycan alditols released from haptoglobin of various cancer samples and normal 
volunteer samples. The EIC at m/z 895.33–895.35 indicates monofucosylated bi-antennary N-glycan alditols (a), the 
EIC at m/z 1077.90-1077.92 indicates monofucosylated tri-antennary N-glycan alditols (b), the EIC at m/z 1260.46-
1260.48 indicates monofucosylated tetra-antennary N-glycan alditols (c), the EIC at m/z 1150.93-1150.95 indicates 
difucosylated tri-antennary N-glycan alditols (d) and the EIC at m/z 1333.49-1333.51 indicates difucosylated tetra-
antennary N-glycan alditols (e) obtained from analyses of various cancer samples and normal volunteer samples. 
Identification of the linkage of fucosylation obtained from the results of digestion with 1-3/4 fucosidase shows that 
the former peaks are due to Lewis-fucosylated N-glycan alditols and the latter peaks are due to core-fucosylated N-
glycan alditols in Fig. a, b, c. On this graphitized carbon column, Lewis-fucosylated N-glycan alditols are eluted earlier 
than the core core-fucosylated N-glycan alditols. Based on this separation principle, fucosylated N-glycans in Fig. d 
and e were identified.  
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Supplementary Fig. 7. The EIC of N-glycan alditols released from haptoglobin in the sera of 
patients with colon cancer (Serum-Hpt) and haptoglobin produced by a human colon 
carcinoma cell line (Cell-Hpt). The EIC at m/z 895.33–895.35 indicates monofucosylated bi-
antennary N-glycan alditol (a) and the EIC at m/z 1260.46–1260.48 indicates 
monofucosylated tetra-antennary N-glycan alditol (b) obtained from analyses of Cell-Hpt and 
Serum-Hpt.
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